COMPASS Pathways

We are discovering and developing a robust pipeline of high potential drug candidates through our risk-contained approach which focuses on validated targets, engages leading experts in neuropsychiatry, applies proven and innovative technologies and maintains rigid criteria for success. Our mission-driven team includes leading scientists, clinicians and business-building executives dedicated to delivering impactful therapies for people with CNS disorders. We apply our expertise in preclinical and clinical neuropsychiatry to identify promising, validated drug targets in areas of high unmet medical need. As our compounds advance through discovery into development, we access our comprehensive network of innovative technologies to design and implement the optimal path for each drug candidate. This purpose-built approach drives higher probability of clinical success by combining DEL and machine learning technologies, in-silico modeling, PET imaging and chem informatics. Psy’s extensive and interconnected system of long-term collaborations provide us access to highly advanced and validated drug discovery and development capabilities. This strategic network increases our R&D productivity throughout the drug development process. Our industry-leading partners share our commitment to changing the standard of CNS treatment and care.

We want to fundamentally change the way neurological and psychiatric conditions are treated. Born out of the Beckley Foundation and underpinned by two decades of scientific research, we are combining world-leading psychedelic science, clinical drug development expertise and a pioneering approach to the use of digital tools in order to optimise patient outcomes, revolutionise treatment and ease the burden these conditions have on patients and society. Due to our unique heritage and science-driven approach, we are able to work with some of the leading specialists in the world and we have established a global network of world-class physicians, scientists and thought leaders to assist us in our efforts to deliver innovative solutions where there is high unmet need. For our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, psychedelic medicines have been a lifelong and intergenerational vocation. Amanda has dedicated over 50 years to the scientific exploration of psychedelics in the belief that modern science can be used to understand, validate, and optimise the healing potential of psychedelic medicines.

At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, Eleusis is the first clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics through conventional clinical development and regulatory approval. Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop and Deliver approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases. Psilocybin is an investigational drug that we believe could transform the treatment of depression. To fully realize the potential of psilocybin, however, we believe a new approach to its formulation is required - an approach targeting a consistent, controllable, and practical delivery of psilocybin’s active ingredient that could make it a mainstream treatment option for depression covered by insurance.

We collaborate with leading scientific and political institutions worldwide to design and develop ground-breaking research and global policy initiatives. Through the Scientific Programme – led by Amanda – we collaborate with leading experts and institutions to design, initiate, and direct scientific research projects, including clinical trials. The studies focus on cannabis, MDMA, and psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT), and explore how these substances act upon the human brain, using the latest developments in neuroscience and brain imaging technology.

We built out the team with clinical, psychiatric and psychedelic specialists who are able to support our clients’ trial design and delivery. The UK is becoming a hub for market leading psychedelic companies, from Compass Pathways to Small Pharma and Beckley Psytech, the largest companies and the most highly anticipated drug candidates are being discovered by British drug developers. We opened Europe’s first commercial research site dedicated to psychedelic trials, grew our team and signed additional clients. Set & Setting: Increased focus on the broader components of psychedelic-assisted therapies, from music and therapy modality to supporting technology and environment. Growing debate: Critical focus on the quality and ethics of trials, access to psychedelic treatment and IP in psychedelic therapies and drug development. Our purpose-built clinic is Europe’s first commercial research site specialising in psychedelics and advanced technologies.

Our goal is to transform the lives of patients with improved therapeutic options. We are focused on designing innovative trials with clinical endpoints directly related to patient benefit, and we seek to recruit patients who will benefit from treatment with our product candidates. Our skills in clinical development define our core expertise in central nervous system disorders.